Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "drug-candidate"

134 News Found

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
News | October 28, 2022

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set


Merck gets fast track designation from the USFDA for anticoagulant therapy
Drug Approval | August 24, 2022

Merck gets fast track designation from the USFDA for anticoagulant therapy

Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis


Ascletis announces IND approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
Drug Approval | August 22, 2022

Ascletis announces IND approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA


Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program
News | July 27, 2022

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.


Enveric Biosciences advances drug development for mental health indications
Biotech | July 16, 2022

Enveric Biosciences advances drug development for mental health indications

Advancing to IND-enabling studies with multiple drug candidates


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Merck KGaA collaborates with University of Bonn to advance molecular machine learning
Digitisation | June 15, 2022

Merck KGaA collaborates with University of Bonn to advance molecular machine learning

The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning


Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
Clinical Trials | June 12, 2022

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials


Tetra Bio-Pharma opens new subsidiary in Australia
News | June 08, 2022

Tetra Bio-Pharma opens new subsidiary in Australia

The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.